Overview of development and formulation of 177Lu-DOTA-TATE for PRRT

Current Radiopharmaceuticals

Volumn 9, Issue 1, 2016, Pages 8-18

  Breeman, Wouter A P ^a   Chan, Ho Sze ^a   De Zanger, Rory M S ^a   Konijnenberg, Mark K ^a   De Blois, Erik ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

177Lu DOTA TATE; DOTA TATE; DOTANOC; DOTATOC; Formulation; PRRT; Radiochemistry

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID COUPLED OCTREOTATE[3 TYROSINE] LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; OCTREOTIDE; ORGANOMETALLIC COMPOUND; RADIOISOTOPE; RECEPTOR; SOMATOSTATIN RECEPTOR;

ARTICLE; CHEMICAL REACTION KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION DOSE; RADIOACTIVE WASTE; RADIOACTIVITY; RADIOCHEMISTRY; RADIOISOTOPE THERAPY; ROBOTICS; ANALOGS AND DERIVATIVES; DRUG DESIGN; METABOLISM; NEUROENDOCRINE TUMORS;

DRUG DESIGN; HUMANS; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE; RECEPTORS, SOMATOSTATIN;

EID: 84949921742     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471008666150313111131     Document Type: Article

References (87)

1. Ansquer, C.; Kraeber-Bodéré, F.; Chatal, J.F. Current status and perspectives in peptide receptor radiation therapy. Curr. Pharm. Des., 2009, 15(21), 2453-2462.
2. Baum, R.P. Peptide receptor radionuclide therapy of neuroendocrine tumors: experience in over 1100 patients and long term results. World J. Nucl. Med., 2013, 12(Suppl. 1), 111-113.
3. Bodei, L.D.; Ferone, C.M.; Grana, M.; Cremonesi, A.; Signore, R.A.; Dierckx, R.A.; Paganelli, G. Peptide receptor therapies in neuroendocrine tumors. J. Endocrinol. Invest., 2009, 32(4), 360-369.
4. Bodei, L.J.; Mueller-Brand, R.P.; Baum, M.E.; Pavel, D.; Horsch, M.S.; O'Dorisio, T.M.; O'Dorisio, J.R.; Howe, M.; Cremonesi, D.J.; Kwekkeboom, D.J.; Zaknun, J.J. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40(5), 800-816.
5. Bodei, L.J.; Mueller-Brand, R.P.; Baum, M.E.; Pavel, D.; Horsch, M.S.; O'Dorisio, T.M.; O'Dorisio, J.R.; Howe, M.; Cremonesi, D.J.; Kwekkeboom, D.J.; Zaknun, J.J. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours (vol 40, pg 800, 2013). Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(3), 584-584.
6. Das, T.S.; Chakraborty, K.G.; Kallur, M.; Venkatesh, M.; Banerjee, S. Preparation of patient doses of 177Lu-DOTA-TATE using indigenously produced 177Lu: the Indian experience. Cancer Biother. Radiopharm., 2011, 26(3), 395-400.
7. Kwekkeboom, D.J.; de Herder, W.W.; van Eijck, C.H.; Kam, B.L.; van Essen, M.; Teunissen, J.J.; Krenning, E.P. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin. Nucl. Med., 2010, 40(2), 78-88.
8. Pool, S.E.; Krenning, E.P.; Koning, G.A.; van Eijck, C.H.; Teunissen, J.J.; Kam, B.; Valkema, R.; Kwekkeboom, D.J.; de Jong, M. Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy. Semin. Nucl. Med., 2010, 40(3), 209-218
9. van Essen, M.; Krenning, E.P.; Kam, B.L.; de Jong, M.; Valkema, R.; Kwekkeboom, D.J. Peptide-receptor radionuclide therapy for endocrine tumors. Nat. Rev. Endocrinol., 2009, 5(7), 382-393.
10. van Essen, M.; Sundin, A.; Krenning, E.P.; Kwekkeboom, D.J. Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nat. Rev. Endocrinol., 2014, 10(2), 102-114.
11. Pach, D.; Sowa-Staszczak, A.; Kunikowska, J.; Królicki, L.; Trofimiuk, M.; Stefańska, A.; Tomaszuk, M.; Głowa, B.; Mikołajczak, R.; Pawlak, D.; Jabrocka-Hybel, A.; Hubalewska-Dydejczyk, A.B. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90YDOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET. Radiother. Oncol., 2012, 102(1), 45-50.
12. Bodei, L.; Mueller-Brand, J.; Baum, R.P.; Pavel, M.E.; Hörsch, D.; O'Dorisio, M.S.; O'Dorisio, T.M.; Howe, J.R.; Cremonesi, M.; Kwekkeboom, D.J.; Zaknun, J.J. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40(5), 800-816.
13. Gupta, S.K.; Singla, S.; Bal, C. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE. Cancer Biother. Radiopharm., 2012, 27(9), 593-599.
14. Gupta, S.K.; Singla, S.; Thakral, P.; Bal, C.S. Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE. Clin. Nucl. Med., 2013, 38(3), 188-194.
15. Kwekkeboom, D.J.; Kam, B.L.; van Essen, M.; Teunissen, J.J.; van Eijck, C.H.; Valkema, R.; de Jong, M.; de Herder, W.W.; Krenning, E.P. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer, 2010, 17(1), R53-R73.
16. de Jong, M., W.A. Breeman, D.J. Kwekkeboom, R. Valkema, and E.P. Krenning, Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc Chem. Res., 2009. 42(7), p. 873-80.
17. Hofman, M.S.; Hicks, R.J. Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized? Eur. J. Nucl. Med. Mol. Imaging, 2014. 41(2), p. 211-3.
18. Bison, S.M.; Konijnenberg, M.W.; Melis, M.; Pool, S.E.; Bernsen, M.R.; Teunissen, J.J.; Kwekkeboom, D.J.; de Jong, M. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin. Transl. Imaging, 2014. 2: p. 55-66.
19. Breeman, W.A.; de Jong, M.; Kwekkeboom, D.J.; Valkema, R.; Bakker, W.H.; Kooij, P.P.; Visser, T.J.; Krenning, E.P. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur. J. Nucl. Med., 2001, 28(9), p. 1421-9.
20. Breeman, W.A.; De Jong, M.; Visser, T.J.; Erion, J.L.; Krenning, E.P. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur. J. Nucl. Med. Mol. Imaging, 2003. 30(6), 917-920.
21. Breeman, W.A.; Kwekkeboom, D.J.; de Blois, E.; de Jong, M.; Visser, T.J.; Krenning, E.P. Radiolabelled regulatory peptides for imaging and therapy. Anticancer Agents Med. Chem., 2007, 7(3), 345-357.
22. Reubi, J.C.; Maecke, H.R. Peptide-based probes for cancer imaging. J. Nucl. Med., 2008. 49(11), 1735-1738.
23. Reubi, J.C.; Schar, J.C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J.S.; Macke, H.R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med., 2000. 27(3), 273-282.
24. Krenning, E.P.; Kwekkeboom, D.J.; Bakker, W.H.; Breeman, W.A.; Kooij, P.P.; Oei, H.Y.; van Hagen, M.; Postema, P.T.; de Jong, M.; Reubi, J.C. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med., 1993. 20(8), 716-731.
25. Kwekkeboom, D.J.; Mueller-Brand, J.; Paganelli, G.; Anthony, L.B.; Pauwels, S.; Kvols, L.K.; O'Dorisio M.; Valkema, R.; Bodei, L. Chinol, M. Maecke, H.R Krenning, E.P. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J. Nucl. Med., 2005, 46(Suppl. 1), 62S-6S.
26. Kwekkeboom, D.J.; Teunissen, J.J.; Bakker, W.H.; Kooij, P.P.; de Herder, W.W.; Feelders, R.A.; van Eijck, C.H.; Esser, J.P.; Kam, B.L.; Krenning, E.P. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol., 2005. 23(12), 2754-2562.
27. Maecke, H.R.; Hofmann, M. Haberkorn, U. (68)Ga-labeled peptides in tumor imaging. J. Nucl. Med., 2005. 46(Suppl 1), 172S-178S.
28. Esser, J.P.; Krenning, E.P.; Teunissen, J.J.; Kooij, P.P.; van Gameren, A.L.; Bakker, W.H.; Kwekkeboom, D.J.; Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT? Eur. J Nucl. Med. Mol. Imaging., 2006, 33(11), 1346-1351.
29. Wehrmann, C.; Senftleben, S.; Zachert, C.; Muller, D.; Baum, R.P. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTANOC. Cancer Biother. Radiopharm., 2007. 22(3), 406-416.
30. Das, T., Bhadwal, M. Banerjee, S. Sarma, H.D. Shinto, A. Kamaleshwaran, K.K. Preparation of DOTA-TATE and DOTANOC freeze-dried kits for formulation of patient doses of Lu-177-labeled agents and their comparison for peptide receptor radionuclide therapy application. J. Radioanal. Nucl. Chem., 2014. 299(3), 1389-1398.
31. de Jong, M.; Rolleman, E.J.; Bernard, B.F.; Visser, T.J.; Bakker, W.H.; Breeman, W.A.; Krenning, E.P. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J. Nucl. Med., 1996, 37(8), p. 1388-92.
32. Rolleman, E.J.; Bernard, B.F.; Breeman, W.A.; Forrer, F.; de Blois, E.; Hoppin, J.; Gotthardt, M.; Boerman, O.C.; Krenning, E.P.; de Jong, M. Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats. Nuklearmedizin, 2008. 47(3), 110-115.
33. Breeman, W.A.P. Practical Aspects of labeling DTPA-and DOTAPeptides with 90Y, 111In, 177Lu, and 68Ga for Peptide-Receptor Scintigraphy and Peptide-Receptor Radionuclide Therapy in Preclinical and Clinical Applications, 2012, The University of New Mexico Health Sciences Center, College of Pharmacy. 34.
34. Breeman, W.A.; De Jong, M.; Bernard, B.F.; Kwekkeboom, D.J.; Srinivasan, A.; van der Pluijm, M.E.; Hofland, L.J.; Visser, T.J.; Krenning, E.P. Pre-clinical evaluation of [111In-DTPA-Pro1, Tyr4]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int. J. Cancer, 1999, 83(5), 657-663.
35. Breeman, W.A.; Hofland, L.J.; de Jong, M.; Bernard, B.F.; Srinivasan, A.; Kwekkeboom, D.J.; Visser, T.J.; Krenning, E.P. Evaluation of radiolabelled bombesin analogues for receptortargeted scintigraphy and radiotherapy. Int. J. Cancer, 1999. 81(4), 658-665.
36. Breeman, W.A.; Kwekkeboom, D.J.; Kooij, P.P.; Bakker, W.H.; Hofland, L.J.; Visser, T.J.; Ensing, G.J.; Lamberts, S.W.; Krenning, E.P. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J. Nucl. Med., 1995. 36(4), 623-627.
37. Breeman, W.A.; VanHagen, M.P.; Visser-Wisselaar, H.A.; van der Pluijm, M.E.; Koper, J.W.; Setyono-Han, B.; Bakker, W.H.; Kwekkeboom, D.J.; Hazenberg, M.P.; Lamberts, S.W.; Visser, T.J.; Krenning, E.P. In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. J. Nucl. Med., 1996, 37(1), 108-117.
38. de Jong, M.; Breeman, W.A.; Bernard, B.F.; van Gameren, A.; de Bruin, E.; Bakker, W.H.; van der Pluijm M.E.; Visser, T.J.; Macke, H.R.; Krenning, E.P. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur. J. Nucl. Med., 1999, 26(7), p. 693-8.
39. Kooij, P.P.; Kwekkeboom, D.J.; Breeman, W.A.P.; Reijs, A.E.M.; Bakker, W.H.; Lamberts, S.W.J.; Visser, T.J.; Krenning, E.P. The effects of specific activity on tissue distribution of [In-111-DTPADPhe1] octreotide in humans. J. Nucl. Med., 1994, 35(5), 226P.
40. Andersson, P.; Forssell-Aronson, E.; Johanson, V.; Wangberg, B.; Nilsson, O.; Fjalling, M.; Ahlman, H. Biokinetics and dosimetry after repeated injections of 111In-DTPA-D-Phe1-Octreotide. in Sixth International Radiopharmaceutical Dosimetry Symposium. 1996. Gatlinburg, Tennessee: Oak Ridge Associated Press.
41. Jonard, P.; Jamar, F.; Walrand, S.; Labar, D.; Mathieu, I.; Smith, C.; Kvols, L.; Krenning, E.P.; Pauwels, S. Effect of peptide amount on biodistribution of Y-86-DOTA-Tyr3-octreotide (SMT487). J. Nucl. Med., 2000, 41(5), 260P.
42. Velikyan, I.; Sundin, A.; Eriksson, B.; Lundqvist, H.; Sorensen, J.; Bergstrom, M.; Langstrom, B. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nucl. Med. Biol., 2010. 37(3), 265-275.
43. Beauregard, J.M.; Hofman, M.S.; Kong, G.; Hicks, R.J. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39(1), 50-56.
44. Kletting, P.; Muller, B.; Erentok B.; Schmaljohann, J.; Behrendt, F.F.; Reske, S.N.; Mottaghy, F.M.; Glatting, G. Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. Med. Phys., 2012, 39(9), 5708-5717.
45. Breeman, W.A.P.; de Blois, E.; Chan, H.S. Determination of peptide content and purity of DOTA-peptides by metal titration and UPLC. J. Radioanal. Nucl. Chem., 2014 (in press).
46. Breeman, W.A.P.; de Zanger, R.; Chan, H.S.; de Blois, E. Alternative method to determine Specific Activity of 177Lu by HPLC. Curr. Radiopharm., 2014 (submitted).
47. Knapp, F.F.; Mirzadeh, S. Beets, A.L.; Du, M. Production of therapeutic radioisotopes in the ORNL High Flux Isotope Reactor (HFIR) for applications in nuclear medicine, oncologyand interventional cardiology. J. Radioanal. Nucl. Chem., 2005, 263(2), 503-509.
48. Le, V.S. Specific Radioactivity of Neutron Induced Radioisotopes: Assessment Methods and Application for Medically Useful 177Lu Production as a Case. Molecules, 2010, 16, 818-846.
49. Mirzadeh, S., Beets, A.L.; Knapp, F.F. Reactor production of lutetium-177 (Lu-177)-An attractive radioisotope for cancer therapy. J. Nucl. Med., 1996, 37(5), 728-728.
50. Pillai, M.R.; Chakraborty, S.; Das, T.; Venkatesh, M.; Ramamoorthy, N. Production logistics of 177Lu for radionuclide therapy. Appl. Radiat. Isot., 2003, 59(2-3), 109-118.
51. Jurisson, S., C. Cutler, and S.V. Smith, Radiometal complexes: characterization and relevant in vitro studies. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(3), 222-234.
52. Moerlein, S.M.; Welch, M.J. The chemistry of gallium and indium as related to radiopharmaceutical production. Int. J. Nucl. Med. Biol., 1981, 8(4), 277-287.
53. Erion, J.L.; Bugaj J.E.; Schmidt M.A.; Wilhelm R.R.; Srinivasan A. High Radiotherapeutic Efficacy of Lu-DOTA-TATE in a Rat Tumor Model. SNM, 1999, 223P.
54. Kwekkeboom, D.J.; Bakker, W.H.; Kooij, P.P.; Konijnenberg, M.W.; Srinivasan, A.; Erion, J.L.; Schmidt, M.A.; Bugaj, J.L.; de Jong, M.; Krenning, E.P. [177Lu-DOTA0,Tyr3]]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur. J. Nucl. Med., 2001, 28(9), 1319-1325.
55. Sosabowski, J.K.; Mather, S.J. Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. Nat. Protoc., 2006, 1(2), 972-976.
56. Liu, S., Edwards, D.S. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem., 2001, 12(1), 7-34.
57. Breeman, W.A.; van der Wansem, K.; Bernard, B.F.; van Gameren, A.; Erion, J.L.; Visser, T.J.; Krenning, E.P.; de Jong, M. The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur. J. Nucl. Med. Mol. Imaging., 2003, 30(2), 312-315.
58. de Blois, E.; Chan, H.S.; Konijnenberg, M.; de Zanger, R.; Breeman, W.A. Effectiveness of quenchers to reduce radiolysis of (111)In-or (177)Lu-labelled methionine-containing regulatory peptides. Maintaining radiochemical purity as measured by HPLC. Curr. Top. Med. Chem., 2012, 12(23), 2677-2685.
59. Asti, M.; Tegoni, M.; Farioli, D.; Iori, M.; Guidotti, C.; Cutler, C.S.; Mayer, P.; Versari, A.; Salvo, D. Influence of cations on the complexation yield of DOTATATE with yttrium and lutetium: a perspective study for enhancing the 90Y and 177Lu labeling conditions. Nucl. Med. Biol., 2011, 39(4), 509-517.
60. Erion, J.L., Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide. Patent, 2008.
61. de Blois, E.; Chan, H.S.; de Zanger, R.; Konijnenberg, M.; Breeman, W.A. Application of single-vial ready-for-use formulation of 111In-or 177Lu-labelled somatostatin analogs. Appl. Radiat. Isot., 2014, 85, 28-33.
62. Maus, S.; de Blois, E.; Ament, S.J.; Schreckenberger, M.; Breeman, W.A.P. Aspects on radiolabeling of 177Lu-DOTATATE: after C18 purification re-addition of ascorbic acid is required to maintain radiochemical purity. Int. J. Diagn. Imaging, 2014, 1, 5-12.
63. Mirzadeh, S.; Mausner, L.F.; Garland, M.A. Reactor-Produced Medical Radionuclides, in Reactor-Produced Medical Radionuclides Handbook of Nuclear Chemistry, 2010, Springer Science Business Media B.V.
64. Bakker, W.H.; Breeman, W.A.; Kwekkeboom, D.J.; De Jong, L.C.; Krenning, E.P. Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate. Q. J. Nucl. Med. Mol. Imaging, 2006, 50(4), 265-271.
65. Eckelman, W.C.; Frank, J.A.; Brechbiel, M. Theory and practice of imaging saturable binding sites. Invest. Radiol., 2002, 37(3), 101-6.
66. Hollenberg, M.D. Receptor Pharmacology and Function, G.R.A. Williams M, Timmermans P.B.M.W.M., ed.; Dekker: New York, 1989, 1-16.
67. Langstrom B.; P.H., Positron emitting tracers in studies of neurotransmission and receptor binding, A.D. Nunn, ed.; Dekker: New York, 1992, 221-266.
68. Bernhardt, P.; Kolby, L.; Johanson, V.; Nilsson, O.; Ahlman, H.; Forssell-Aronsson, E. Biodistribution of 111In-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration. Nucl. Med. Biol., 2003, 30(3), 253-260.
69. Breeman, W.A.; de Jong, M.; Bernard, B.F.; Bakker, W.H.; Rolleman, E.J.; Kwekkeboom, D.J.; Visser, T.J.; Krenning, E.P. Effects of ligand priming and multiple-dose injection on tissue uptake of 111In-pentetreotide in rats. Nucl.Med. Biol., 1997, 24(8), 749-753.
70. Espenan, G.D.; Nelson, J.A.; Fisher, D.R.; Diaco, D.S.; McCarthy, K.E.; Anthony, L.B.; Maloney, T.J.; Woltering, E.A.; Experiences with high dose radiopeptide therapy: the health physics perspective. Health Phys., 1999, 76(3), 225-235.
71. Kratochwil, C.; Giesel, F.L.; Lopez-Benitez, R.; Schimpfky, N.; Kunze, K.; Eisenhut, M.; Kauczor, H.U.; Haberkorn, U. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin. Cancer. Res., 2010, 16(10), 2899-905.
72. Kratochwil, C.; Lopez-Benitez, R.; Mier, W.; Haufe, S.; Isermann, B.; Kauczor, H.U.; Choyke, P.L.; Haberkorn, U.; Giesel, F.L. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr. Relat.Cancer, 2011, 18(5), 595-602.
73. Pool, S. [111In-DTPA]octreotide tumor uptake in GEPNET liver metastasis after intra-arterial administration-an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy. CNBR, 2014 (in press).
74. Cheng, J.; Hong, D.; Zhu, G.; Swanstrom, L.L.; Hansen, P.D.; Laparoscopic placement of hepatic artery infusion pumps: technical considerations and early results. Ann. Surg. Oncol., 2004, 11(6), 589-597.
75. Fani, M.; Andre, J.P.; Maecke, H.R. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol. Imaging, 2008, 3(2), 67-77.
76. Mansi, R.; Wang, X.; Forrer, F.; Kneifel, S.; Tamma, M.L.; Waser, B.; Cescato, R.; Reubi, J.C.; Maecke, H.R.; Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acidconjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin.Cancer Res., 2009, 15(16), 5240-5249.
77. Mansi, R.; Wang, X.; Forrer, F.; Waser, B.; Cescato, R.; Graham, K.; Borkowski, S.; Reubi, J.C.; Maecke, H.R. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPrpositive tumours. Eur. J. Nucl. Med. Mol. Imaging, 2011, 38(1), 97-107.
78. Wang, X.; Fani, M.; Schulz, S.; Rivier, J.; Reubi, J.C.; Maecke, H.R. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. Eur. J. Nucl. Med. Mol Imaging, 2012, 39(12), 1876-1885.
79. Giesel, F.L.; Wulfert, S.; Zechmann, C.M.; Haberkorn, U.; Kratochwil, C.; Flechsig, P.; Kuder, T.; Schwartz, L.H.; Bruchertseifer, F. Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy. Exp. Oncol., 2013, 35(2), 122-126.
80. Nayak, T.; Norenberg, J.; Anderson, T.; Atcher, R. A comparison of high-versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro. Cancer Biother Radiopharm, 2005, 20(1), 52-57.
81. Norenberg, J.P.; Krenning, B.J.; Konings, I.R.; Kusewitt, D.F.; Nayak, T.K.; Anderson, T.L.; de Jong, M.; Garmestani, K.; Brechbiel, M.W.; Kvols, L.K. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin. Cancer Res., 2006, 12(3 Pt. 1), 897-903.
82. Raymond, E.; Dahan, L.; Raoul, J.L.; Bang, Y.J.; Borbath, I.; Lombard-Bohas, C.; Valle, J.; Metrakos, P.; Smith, D.; Vinik, A.; Chen, J.S.; Horsch, D.; Hammel, P.; Wiedenmann, B.; Van Cutsem, E.; Patyna, S.; Lu, D.R.; Blanckmeister, C.; Chao R.; Ruszniewski, P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med., 2011, 364(6), 501-513.
83. Yao, J.C.; Shah, M.H.; Ito, T.; Bohas, C.L.; Wolin, E.M.; Van Cutsem, E.; Hobday, T.J.; Okusaka, T.; Capdevila, J.; de Vries, E.G.; Tomassetti, P.; Pavel, M.E.; Hoosen, S.; Haas, T.; Lincy, J.; Lebwohl, D.; Oberg, K. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med., 2011, 364(6), 514-523.
84. Strosberg, J.R.; Fine, R.L.; Choi, J.; Nasir, A.; Coppola, D.; Chen, D.T.; Helm, J.; Kvols, L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 2011, 117(2), 268-275.
85. Zhernosekov, K.P.; Perego, R.C.; Dvorakova, Z. R.; Henkelmann, Turler A. Target burn-up corrected specific activity of 177Lu produced via 176Lu(n, gamma) 177Lu nuclear reactions. Appl. Radiat. Isot., 2008, 66(9), 1218-1220.
86. Chakravarty, R.; Das, T.; Dash, A.; Venkatesh, M. An electroamalgamation approach to isolate no-carrier-added 177Lu from neutron irradiated Yb for biomedical applications. Nucl. Med. Biol., 2010, 37(7), 811-20.
87. Lebedev, N.A.; Novgorodov, A.F.; Misiak, R.; Brockmann, J.; Rosch, F. Radiochemical separation of no-carrier-added 177Lu as produced via the 176Yb(n,gamma)177Yb->177Lu process. Appl. Radiat. Isot., 2000, 53(3), 421-425.